EyePoint, Inc. is under investigation by Pomerantz LLP for potential securities fraud following disappointing Phase 3 trial results for its drug DURAVYU™. The trial failed to meet its primary endpoint compared to a competitor drug, leading to a 66.98% drop in EyePoint's stock price on August 17, 2026. The investigation will determine if EyePoint and its executives engaged in unlawful business practices. Investors affected by the stock drop are encouraged to contact Pomerantz LLP for possible legal action.
EyePoint, Inc. is the subject of a legal investigation following its Phase 3 trial results. For readers following the health sector, here is Pluang's market snapshot as of Sep 17, 2026 21:11 WIB: out of 91 priced health-sector US stocks, 59 rose and 31 fell. Notable movers include SANA at USD 3.12 with a 6.85% increase, INO at USD 1.22 with a 6.09% increase, and ABCL at USD 12.38 with a 6.08% increase.
Fluence Energy's stock price target was cut sharply from $15.00 to $4.00 by RBC Capital analyst Christopher Dendrinos after the company slashed its 2026 revenue forecast from $3.00 billion to $2.40 billion. The company now expects an adjusted EBITDA ...
Regency Centers reported solid Q2 2026 results with Funds From Operations (FFO) at $1.21 per share and a 3.8% growth in same-property Net Operating Income (NOI). The company raised its full-year guidance, signaling confidence in continued growth. Reg...
Ciena reported a 37% revenue increase to $1.67 billion and a 215% rise in adjusted EPS to $2.11 in its fiscal third quarter, driven by strong demand from AI and cloud infrastructure. The company is well positioned to benefit from the AI networking ma...
Maureen Gellerman, Chief Human Resources Officer at Five Below, sold 1,610 shares of the company, generating $401,000 from the transaction. This insider sale may indicate personal financial planning or portfolio rebalancing but does not necessarily r...
ON Semiconductor is focusing on advanced power-density technologies for AI data centers and electric vehicles, aiming for $2.5 billion revenue from AI alone by 2030. Despite a Neutral rating from UBS, the company introduced its Embedded Power Platfor...
